- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04395274
Young Adult EC Use and Respiratory Outcomes
November 7, 2023 updated by: Alayna Tackett, Ohio State University Comprehensive Cancer Center
E-cigarette (EC) use continues to increase among youth, and EC may be detrimental to youth respiratory health.
Public health officials and the Food and Drug Administration (FDA) can now regulate ECs.
The proposed study uses naturalistic assessments called ecological momentary assessment (EMA) to understand how ECs use may impact the respiratory health of youth and young adult users compared to never-using peers.
Study Overview
Detailed Description
Using a prospective longitudinal design, 150 youth and young adults aged 18-25 years (100 exclusive-EC users; 50 never-users) will complete 5 sessions (baseline, 3-,6-, 9-, and 12-months).
Sessions will include naturalistic measures such as measures of respiratory health, questionnaires, and nasal epithelial lining fluid (NELF) nasal samples.
To assess acute changes in pulmonary functioning related to tobacco product use, participants will complete twice daily EMA and home-based spirometry for the 2 weeks following the Day 1 session and the 2 weeks prior to each follow-up zoom session.
Never-users will participate in a brief 15-30-minute individual interview consisting of questions related to reasons for never-EC use and other protective factors that will be used to build future prevention messaging.
Study Type
Observational
Enrollment (Estimated)
300
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: The Ohio State University Comprehensive Cancer Center
- Phone Number: 800-293-5066
- Email: OSUCCCClinicaltrials@osumc.edu
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43214
- Recruiting
- The Ohio State University
-
Contact:
- Logan Miller
- Phone Number: 844-744-2447
- Email: Tackett-Lab@osumc.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
15 years to 21 years (Adult)
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample
Study Population
The present proposal, a study of e-cigarette use among youth and young adults, will include both females and racial/ethnic minorities.
Description
Inclusion Criteria:
- own a smartphone and willing to add study EMA and spirometry application to it.
- a current exclusive-EC user (endorse ≥weekly use over the past 3 months) and report never trying OTPs
- between the ages of 18-25 years old at the time of enrollment
- read and speak English
- willing to complete five, 2-week periods of daily EMA and home-based spirometry
- never-users must indicate never trying any tobacco product to be eligible for enrollment
Exclusion Criteria:
- self-reported diagnosis of lung disease including cystic fibrosis or chronic obstructive pulmonary disease; we will not exclude youth who have asthma, but will incorporate this as a covariate during analyses
- unstable or significant psychiatric conditions (past and stable conditions will be allowed)
- history of cardiac event or distress within the past 3 months
- are currently pregnant, planning to become pregnant, or breastfeeding
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Current E-Cigarette Users
Monitoring current e-cigarette users
|
Never E-Cigarette / Tobacco Users
Monitoring never users of any tobacco or e-cigarette products.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Spirometry to measure the change from baseline in forced vital capacity (FVC)
Time Frame: Baseline, 3-month, 6-month, 9-month, 12-month
|
Spirometry (a pulmonary function diagnostic test) will be completed during each session.
For e-cigarette users, assessments will be completed in session.
|
Baseline, 3-month, 6-month, 9-month, 12-month
|
Spirometry to measure the change from baseline in forced expiratory volume (FEV)
Time Frame: Baseline, 3-month, 6-month, 9-month, 12-month
|
Spirometry (a pulmonary function diagnostic test) will be completed during each session.
For e-cigarette users, assessments will be completed in session.
|
Baseline, 3-month, 6-month, 9-month, 12-month
|
Level of dependence by product type will be examined.
Time Frame: Baseline, 3-month, 6-month, 9-month, 12-month
|
Changes in product use evaluated with an evaluation of the changes in dependence using the Hooked on Nicotine Checklist (HONC).
|
Baseline, 3-month, 6-month, 9-month, 12-month
|
Respiratory health measures by nasal swab.
Time Frame: Baseline, 3-month, 6-month, 9-month, 12-month
|
Nasal epithelial lining fluid (NELF) samples will provide objective data on respiratory health (e.g., markers of inflammation, host defense, and lung injury) and will provide estimates of nicotine exposure/use via cotinine (i.e., the predominate metabolite of nicotine) will also be examined to provide objective indicators of recency of EC and/or OTP use.
|
Baseline, 3-month, 6-month, 9-month, 12-month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Alayna Tackett, PhD, The Ohio State Comprehensive Cancer Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 15, 2021
Primary Completion (Estimated)
May 15, 2024
Study Completion (Estimated)
July 15, 2024
Study Registration Dates
First Submitted
April 21, 2020
First Submitted That Met QC Criteria
May 14, 2020
First Posted (Actual)
May 20, 2020
Study Record Updates
Last Update Posted (Actual)
November 9, 2023
Last Update Submitted That Met QC Criteria
November 7, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- OSU-23006
- 1K01HL148907-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on E Cig Use
-
Yale UniversityNational Institute on Drug Abuse (NIDA)Not yet recruiting
-
Sun Yat-sen UniversityRecruiting
-
Sun Yat-sen UniversityCompleted
-
Virginia Commonwealth UniversityRecruiting
-
Yale UniversityAmerican Heart AssociationRecruiting
-
University of VirginiaDuke UniversityRecruiting
-
University of Massachusetts, WorcesterNational Institute on Drug Abuse (NIDA)Completed
-
University of PennsylvaniaNational Cancer Institute (NCI)Not yet recruitingSmoking | Tobacco Use | Cigarette Smoking | E-Cig Use
-
Achieve Life SciencesCompletedVaping | E-Cig UseUnited States
-
Yale UniversityCompleted
Clinical Trials on Other
-
University of MinnesotaCompleted
-
Institute of Liver and Biliary Sciences, IndiaNot yet recruitingDecompensated CirrhosisIndia
-
Ruijin HospitalNot yet recruitingLymphoma | DLBCL - Diffuse Large B Cell LymphomaChina
-
Hugo W. Moser Research Institute at Kennedy Krieger...Johns Hopkins UniversityRecruitingADHD | Attention Deficit Hyperactivity DisorderUnited States
-
Cutera Inc.CompletedAcne Scars - Mixed Atrophic and HypertrophicUnited States
-
Capital Medical UniversityQilu Hospital of Shandong University; Beijing Chao Yang Hospital; Qingdao Municipal... and other collaboratorsUnknownCommunity Acquired PneumoniaChina
-
Washington University School of MedicineRecruitingDepression | Coronary Heart DiseaseUnited States
-
Aarogyam UKUniversity of Warwick; NMP Medical Research Institute; Mothers Touch FoundationCompleted
-
AmgenCompletedRelapsed/Refractory Acute Lymphoblastic LeukemiaUnited States
-
University of LeicesterUniversity Hospitals, Leicester; Leicester City Clinical Commissioning Group; West Leicestershire Clinical Commissioning Group and other collaboratorsCompletedCardiovascular Diseases | Chronic Kidney Diseases | Cardiovascular Risk FactorUnited Kingdom